Is serum TWEAK a useful biomarker of neuropsychiatric systemic lupus erythematosus?

The aim of this study was to determine the role of the tumor necrosis factor like weak inducer of apoptosis (TWEAK) as a serum biomarker of neuropsychiatric involvement in systemic lupus erythematosus (NPSLE). Levels of TWEAK levels were measured in sera of 92 patients with systemic lupus erythematosus (SLE), including 28 patients with neuropsychiatric lupus, and in 59 healthy controls using ELISA. All SLE patients underwent rheumatological, neurological and psychiatric assessment. We found no significant differences in TWEAK levels, between SLE patients and the healthy controls (p=0.2411). Similarly, no difference was observed between subgroup of NPSLE and healthy controls (p=0.7658). The mean SLE disease activity (SLEDAI) was 13.25. No correlations between TWEAK levels with disease activity (SLEDAI, r=0.2113, p=0.2805) or the most common NPSLE manifestations such as headache (r=0.2079), seizures (r=0.1101), cerebrovascular disease (r= 0.2347), cognitive dysfunction (r=0.1597) and anxiety (r=0.1397) were observed. Our data do not support the use of serum TWEAK as a discriminating biomarker for NPSLE. The role of the TWEAK in NPSLE remains to be investigated.

[1]  S. Hirohata,et al.  Association of antibodies to the NR1 subunit of N-methyl-D-aspartate receptors with neuropsychiatric systemic lupus erythematosus , 2016, Modern rheumatology.

[2]  L. Llorente,et al.  Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erhytematosus , 2016, Lupus.

[3]  T. Yoshio,et al.  IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus , 2016, Lupus.

[4]  Yi Zhao,et al.  Role of the TWEAK/Fn14 pathway in autoimmune diseases , 2016, Immunologic research.

[5]  T. Kasama,et al.  Clinical Features of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Other Connective Tissue Diseases , 2016, Clinical medicine insights. Arthritis and musculoskeletal disorders.

[6]  T. Huizinga,et al.  Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives , 2016, Drugs.

[7]  G. Tsivgoulis,et al.  EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. , 2015, Rheumatology.

[8]  M. Schwartz,et al.  TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. , 2015, Journal of autoimmunity.

[9]  L. Caniatti,et al.  Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. , 2015, Rheumatology.

[10]  G. Valesini,et al.  Neuropsychiatric manifestations associated with anti-endothelial cell antibodies in systemic lupus erythematosus. , 2015, The Israel Medical Association journal : IMAJ.

[11]  Ian Giles,et al.  Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. , 2015, Autoimmunity reviews.

[12]  W. Chung,et al.  Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions , 2015, Rheumatology International.

[13]  J. Hanly.  Diagnosis and management of neuropsychiatric SLE , 2014, Nature Reviews Rheumatology.

[14]  A. Ramos,et al.  Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease , 2014, Current opinion in nephrology and hypertension.

[15]  M. Khrestchatisky,et al.  Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases? , 2013, Front. Immunol..

[16]  C. Putterman,et al.  Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. , 2013, Journal of autoimmunity.

[17]  M. Frieri.  Mechanisms of disease for the clinician: systemic lupus erythematosus. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  M. van Buchem,et al.  Prospective Study of Clinical Phenotypes in Neuropsychiatric Systemic Lupus Erythematosus; Multidisciplinary Approach to Diagnosis and Therapy , 2012, The Journal of Rheumatology.

[19]  Zhu Xuejing,et al.  Urinary TWEAK Level as a Marker of Lupus Nephritis Activity in 46 Cases , 2012, Journal of biomedicine & biotechnology.

[20]  D. Ye,et al.  Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus , 2012, Clinical Rheumatology.

[21]  J. Yazdany.  Health‐related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus‐Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire (L‐QoL) , 2011, Arthritis care & research.

[22]  A. Popescu,et al.  Neuropsychiatric Systemic Lupus Erythematosus , 2011, Current neuropharmacology.

[23]  S. Marzouk,et al.  Correlations of Urinary Biomarkers, TNF-Like Weak Inducer of Apoptosis (TWEAK), Osteoprotegerin (OPG), Monocyte Chemoattractant Protein-1 (MCP-1), and IL-8 with Lupus Nephritis , 2011, Journal of Clinical Immunology.

[24]  X. Ao,et al.  Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. , 2011, Cytokine.

[25]  Neil J Scolding,et al.  Neurolupus , 2010, Practical Neurology.

[26]  I. Bruce,et al.  Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus , 2009, Annals of the rheumatic diseases.

[27]  B. Rovin,et al.  Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study , 2009, Arthritis research & therapy.

[28]  Irene Jarchum,et al.  TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. , 2009, Cytokine.

[29]  M. Ermani,et al.  Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. , 2009, Journal of autoimmunity.

[30]  L. Burkly,et al.  TWEAK is expressed at the cell surface of monocytes during multiple sclerosis , 2008, Journal of leukocyte biology.

[31]  W. T. El-Sherif,et al.  Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement. , 2009, The Egyptian journal of immunology.

[32]  C. Filley,et al.  Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. , 2008, Arthritis and rheumatism.

[33]  J. Winkles.  The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting , 2008, Nature Reviews Drug Discovery.

[34]  S. Hirohata,et al.  Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. , 2008, Arthritis and rheumatism.

[35]  R. Morris,et al.  Flow cytometric assessment of anti-neuronal antibodies in central nervous system involvement of systemic lupus erythematosus and other autoimmune diseases , 2008, Lupus.

[36]  I. Bruce,et al.  Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. , 2007, Arthritis and rheumatism.

[37]  B. Rovin,et al.  Urinary TWEAK and the activity of lupus nephritis. , 2006, Journal of autoimmunity.

[38]  M. Yepes,et al.  Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Increases the Permeability of the Neurovascular Unit through Nuclear Factor-κB Pathway Activation , 2005, The Journal of Neuroscience.

[39]  J. Hanly,et al.  Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. , 2004, The Journal of rheumatology.

[40]  W. Brooks,et al.  The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. , 2002, The Journal of rheumatology.

[41]  Caroline Gordon,et al.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. , 1999, Arthritis and rheumatism.

[42]  D. Isenberg,et al.  A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[43]  S. Hirohata,et al.  Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. , 1998, Arthritis and rheumatism.

[44]  S. Abramson,et al.  Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. , 1996, Arthritis and rheumatism.

[45]  R. Cervera,et al.  1982 Revised Criteria for Classification of Systemic Lupus Erythematosus — Ten Years Later , 1993, Lupus.

[46]  R. Lahita,et al.  Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. , 1979, Arthritis and rheumatism.